$RKT.LN being panicked sold on a $60m legal verdict. It seems impossible to prove whether RKT is to blame, but that seems irrelevant in a jury based system. Easy to draw a parallel to Bayer. 12x P/E for a consumer staple growing MSD with only 1.5x ND / EBITDA. Tweet added by Roojoo @roojoo3

Roojoo

3 months

$RKT.LN being panicked sold on a $60m legal verdict. It seems impossible to prove whether RKT is to blame, but that seems irrelevant in a jury based system. Easy to draw a parallel to Bayer. 12x P/E for a consumer staple growing MSD with only 1.5x ND / EBITDA.

1

0

6

Pieter Tobback, CFA

@PieterTobback

3 months

@roojoo3 True - although it doesn’t feel too comfortable if you draw Bayer parallels😏

1

0

Roojoo

@roojoo3

3 months

@PieterTobback That's why everyone is selling. The typical consumer staple wants a reliable dividend, no difficult litigation risk.

1

0

2

Replies